TG THERAPEUTICS, INC. short interest in 2026
In 2026, TG THERAPEUTICS, INC.'s disclosed short interest ran from 17.19% of shares outstanding on 15 Jan 2026 to 19.70% on 15 Sep 2026, a change of +2.51 percentage points. The year's high was 20.05% on 15 Jul 2026 and its low 17.02% on 30 Apr 2026, averaging 18.63% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.57 days on 29 May 2026. Full history: TG THERAPEUTICS, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 17.19% (15 Jan 2026)
- End of year
- 19.70% (15 Sep 2026)
- Change
- +2.51 pp
- High
- 20.05% (15 Jul 2026)
- Low
- 17.02% (30 Apr 2026)
- Average
- 18.63%
- Highest days to cover
- 21.57 (29 May 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 17.19% | 8.33 | |
| 30 Jan 2026 | 18.24% | 17.58 | |
| 13 Feb 2026 | 18.46% | 18.94 | |
| 27 Feb 2026 | 17.34% | 17.16 | results (8-K), 10-K filed |
| 13 Mar 2026 | 17.73% | 17.37 | |
| 31 Mar 2026 | 18.23% | 11.04 | |
| 15 Apr 2026 | 18.09% | 19.11 | |
| 30 Apr 2026 | 17.02% | 13.89 | |
| 15 May 2026 | 18.36% | 10.18 | 10-Q filed, results (8-K) |
| 29 May 2026 | 18.41% | 21.57 | |
| 15 Jun 2026 | 19.73% | 12.12 | |
| 30 Jun 2026 | 19.71% | 8.29 | |
| 15 Jul 2026 | 20.05% | 15.45 | |
| 31 Jul 2026 | 19.15% | 13.62 | |
| 14 Aug 2026 | 19.67% | 12.59 | results (8-K), 10-Q filed |
| 31 Aug 2026 | 19.68% | 15.86 | |
| 15 Sep 2026 | 19.70% | 18.54 |
See also: TG THERAPEUTICS, INC.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.